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Tricyclic antidepressants for migraine and tension-type
headaches
Are largely beneficial, but a lack of research leaves important clinical questions unanswered
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In the linked meta-analysis (doi:10.1136/bmj.c5222), Jackson
and colleagues assess the efficacy of tricyclic antidepressants
in the treatment of migraine, tension headache, and mixed
headache.
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Tricyclic antidepressants have a long history in the treatment
of headache. In 1964 Lance and Curran reported a better
response to amitriptyline (30-75 mg/day) in chronic tension
headache (n=280) compared with 11 other commonly used
drugs (such as benzodiazepines, vasodilators, and sedatives).
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They also reported a placebo controlled crossover trial of 27
patientsthatshowedclinicallysignificantimprovements(≥50%
reduction)inheadachesin55%ofpatientstakingamitriptyline,
but only 11% of those taking placebo. When the results for
amitriptyline were aggregated across the two studies, the effect
of amitriptyline became more pronounced over time, was
independent of the presence of depression, was evident in
patientswithcontinuousaswellasepisodicheadaches,andwas
most pronounced in older (≥60 year of age) patients. A decade
passed before similar positive findings were reported for
migraine.
3
With replication of these findings tricyclic antidepressants,
particularlyamitriptyline,havebeenrecommendedintextbooks
for at least 35 years. With the advent of formal treatment
guidelinesforheadache,tricyclicsalsohavebeenrecommended
inclinicalguidelinesforthetreatmentoftension-typeheadache
and migraine.
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Thecurrentmeta-analysisupdatestheevidencebasefortricyclic
antidepressants in the treatment of migraine and tension
headache.
1Resultsfromthe37trialsoftricyclicantidepressants
areanalysed;the20placebocontrolledtrialsprimarilyevaluate
amitriptyline (14 trials) or clomipramine (four trials). The
meta-analysis largely confirms Lance and Curran’s original
observations. Across trials, low dose tricyclic antidepressants
(mean amitriptyline dose 80 mg/day) reduced headache by at
least 50% compared with placebo (tension: relative risk 1.41,
95% confidence interval 1.02 to 1.89; migraine: 1.80, 1.24 to
2.62). The proportion of people who stopped treatment did not
differ significantly between people taking tricyclic
antidepressants or placebo. Treatment effects increased over
time.Otherpreventivedrugs(topiramateorβblockers)showed
no advantage over tricyclic antidepressants. Tricyclic
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Video on bmj.com (see also http://bmj.com/video)
Related film on migraine:This video presents some of the latest research into the causes of this debilitating condition. It also highlights the current
best practice for drug therapy, and discusses whether complementary therapies can play a role in treating migraine.
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EDITORIALSantidepressantsweresignificantlymoreeffectivethanserotonin
reuptake inhibitors (tension (four trials): 1.73, 1.34 to 2.22;
migraine (five trials): 1.72, 1.15 to 2.55), although dry mouth,
drowsiness, and weight gain were also significantly more
common with tricyclics.
Conclusions that can be drawn from meta-analyses depend on
thenumberandqualityofavailabletrials.Astheauthorsrightly
point out, the number of studies was not large and most were
smallandofshortduration(average11weeks).Moreover,most
trialswouldnotmeetcurrentmethodologicalstandardsbecause
80%(16/20)ofplacebocontrolledtrialswerecompletedatleast
20 years ago.
7 8 As a result, convincing evidence is available
for only the most general conclusion: amitriptyline is more
effective than placebo for migraine and tension headache.
Amitriptyline also seems to be more effective than serotonin
reuptake inhibitors, although few direct comparisons are
available.
After a half century of research the most important clinical
questions remain unanswered. Is the observed effect of
amitriptyline a true class effect of tricyclic antidepressants or
specifictoasubsetoftricyclics?Arenewerselectivedualaction
(serotonin and noradrenaline) antidepressants as effective as
tricyclic antidepressants with, potentially, a more favourable
side effect profile? How does the effectiveness of tricyclic
antidepressants compare with other preventive drugs or with
non-drug treatments? Which people are the best candidates for
tricyclic antidepressants rather than other preventive drugs or
non-drug treatments? Can tricyclic antidepressants be
beneficially combined with other preventive drugs or non-drug
treatments in people who do not respond to monotherapy?
Secondary analyses of available clinical trial data can yield
answers to some of these questions.
9 However, just a few large
properly designed trials might answer many of these questions,
as well as other clinically relevant questions.
Unfortunately, a 50 year history indicates that such trials will
not be conducted. Incentives are too few and disincentives too
substantial for the drug industry to conduct such trials. The
establishment of a combination of incentives and requirements
to encourage the industry to provide information about
comparativeeffectivenessandotherclinicallyrelevantquestions
during premarket approval or postmarket research is unlikely
to occur. Thus, support from government health agencies or
fromotherhealthcareplayerswithaninterestinidentifyingcost
effective treatments will be needed in addition to existing
examples of government funded trials.
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